The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (15 analysts) rates it hold, with a mean price target of $25. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Bath & Body Works, Inc.
BBWI · the NYSE · USD · Market cap $4.3B · 9,071 employees
Bath & Body Works, Inc.
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price18.91 USD at the 19 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.43)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $22.26 to $36.17, base estimate $23.52 (screen dated 2026-11-19).
- Trend Accumulation
- Insiders insiders sold, $14, latest filing 2026-10-16
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.43, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Bath & Body Works, Inc. holds its Accumulation at $18.91. The statistical read favours the sellers, held for 193 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 193 days |
| Price at the screen | $18.91 |
| Valuation | 5.62 trailing · 7.68 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.33 |
Five Screens: BBWI's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 135.05% | Below 33% | Fail |
| Interest-bearing cash | 25.98% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Bath & Body Works,'s business is in a permissible area, but its interest-bearing debt is about 135% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BBWI's ethical verdict changes
Today BBWI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 20% discount to our $23.52 fair value, weak competitive moat.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 19.6% discount to the base estimate.
Third-party analyst targets: 15 covering, consensus Hold. The average target sits +16% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $23.52, with a range of $22.26 to $36.17, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsDebt burden outweighs any bargain in bath products
Every time someone reaches for a three wick candle or a bottle of lotion the retailer behind it is already carrying more debt than its balance sheet can comfortably support. We pass because the company fails the ethical screen on that leverage, leaving no margin for the kind of shocks that hit specialty retail hard.
Revenue is shrinking three percent while the forward multiple sits at seven times earnings. That looks cheap until you remember this is a cyclical business with a weak moat and margins that can compress quickly when spending slows. The fifteen analysts see it as a hold with targets barely above the current price, which tells you the market is not pricing in much recovery.
High debt plus negative growth creates exactly the sort of value trap that appears attractive on paper but rarely rewards patience. Analysis, not advice.
| Forward P/E | 7.7xvery cheap relative to earnings |
| Trailing P/E | 5.6xvery cheap relative to earnings |
| EPS, trailing | 3.80 |
| EPS, forward | 2.78 |
| Revenue growth | -2.3%revenue is shrinking |
| Profit margin | 10.8%thin but positive margins |
| FCF yield | 17.75% |
| Dividend yield | 4.35% |
| Current ratio | 1.20adequate liquidity, worth monitoring |
| Beta | 1.33moves a little more than the market |
| Short interest, float | 0.09% |
| 52-week range | 14.28 - 24.94 |
| Moat | WEAK |
| Market cap | $4.3B |
| Employees | 9,071 |
BBWI-specific watchpoints · The things to watch: it already moves more than the market on an average day.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Ross Stores' Q3 Earnings Coming Up: Key Insights for Investors Yahoo Finance · 7d ago
- Gap Set to Report Q3 Earnings: Here's What Investors Should Know Yahoo Finance · 7d ago
- Bath & Body Works (BBWI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Yahoo Finance · 8d ago
- Top 5 Activist Target Stocks for Spin-offs or Breakups Yahoo Finance · 10d ago
- PREP Property Group Acquires Promenade at Casa Grande in Growing Phoenix-Tucson Corridor Yahoo Finance · 10d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Nash Sarah E | Dir | S - Sale | 1 | $14 |
| 2026-05-19 | MAZUREK THOMAS E | Officer | 6,616 | · | |
| 2026-03-12 | MAZUREK THOMAS E | Officer | 40,921 | · | |
| 2026-03-12 | HEAF DANIEL | Chief Executive Officer | 212,993 | · | |
| 2026-03-12 | BORATTO EVA C | Chief Financial Officer | 115,815 | · | |
| 2025-11-24 | NASH SARAH E | Director | 10,000 | $155,800 | |
| 2025-11-24 | SYMANCYK JAMES KEVIN | Director | 22,500 | $350,550 | |
| 2025-11-21 | VOSKUIL STEVEN E | Director | 20,000 | $300,700 | |
| 2025-11-21 | STEINOUR STEPHEN D | Director | 6,700 | $99,528 | |
| 2025-11-21 | HONDAL FRANCIS A | Director | 3,343 | $50,128 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $19.84 | -6.0% | · | $941 | -6.0% |
| 2 months | $17.40 | +7.2% | · | $1,072 | +7.2% |
| 3 months | $19.44 | -4.0% | $0.20 | $970 | -3.0% |
| 6 months | $17.38 | +7.4% | $0.40 | $1,097 | +9.7% |
| 1 year | $20.22 | -7.7% | $0.80 | $962 | -3.8% |
| 2 years | $29.37 | -36.5% | $1.60 | $690 | -31.0% |
| 3 years | $27.02 | -31.0% | $2.20 | $772 | -22.8% |
| 5 years | $67.45 | -72.3% | $3.80 | $333 | -66.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BBWI does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.